x

Search for a research project

* (*) mandatory field

46 Result(s)

Sort by

Funded by an IRDiRC member =

Research projects

AUSTRIA

WIEN
WIEN

Overcoming Neuroblastoma Tumour HETerogeneity, Resistance and RecurrAnCe (ONTHETRRAC)
St. Anna Kinderkrebsforschung
Children's Cancer Research Institute

BELGIUM

OOST-VLAANDEREN
GENT

BELGIUM

OOST-VLAANDEREN
GENT

FRANCE

ILE-DE-FRANCE
PARIS

Genetics and molecular bases of central hypoventilation syndromes (Ondine's Curse)
CHU Paris - Hôpital Necker-Enfants Malades
Laboratoire de Génétique Moléculaire

FRANCE

ILE-DE-FRANCE
PARIS

Genetics and molecular bases of malformative syndromes with tumour predisposition
CHU Paris - Hôpital Necker-Enfants Malades
Laboratoire de Génétique Moléculaire

GERMANY

Baden-Württemberg
HEIDELBERG

GERMANY

Baden-Württemberg
HEIDELBERG

MYCN and MYC-regulated stem cell markers as therapeutic targets in neuroblastoma
Deutsches Krebsforschungszentrum
Abteilung Tumorgenetik

GERMANY

Baden-Württemberg
HEIDELBERG

Characterization of the neuroblastoma trancriptome
Deutsches Krebsforschungszentrum
Abteilung Tumorgenetik

GERMANY

Baden-Württemberg
HEIDELBERG

1p aberrations and prognostic variables in neuroblastoma
Deutsches Krebsforschungszentrum
Abteilung Tumorgenetik

GERMANY

Baden-Württemberg
HEIDELBERG

INFORM-Registry: INdividualized Therapy FOr Relapsed Malignancies in Childhood
Deutsches Krebsforschungszentrum
Klinische Kooperationseinheit Pädiatrische Onkologie

GERMANY

Nordrhein-Westfalen
KÖLN

Molecular basis for tumor suppression and spontanous regression in neuroblastoma
Universitätsklinikum Köln
Pädiatrische Onkologie und Hämatologie

GERMANY

Sachsen
LEIPZIG

The critical (primary) function of MYCN and the prognostical value of MYCN related signaling in neuroblastoma
Zentrum für Frauen- und Kindermedizin am Universitätsklinikum Leipzig
Abteilung für Pädiatrische Onkologie, Hämatologie und Hämostaseologie

KOREA, REPUBLIC OF

KOREA, REPUBLIC OF
SEOUL

SPAIN

Cataluña
BARCELONA

Funded by an IRDiRC memberMicroRNA-based nanotherapy: New treatment for pediatric tumors of the nervous system
Vall d'Hebron Institut de Recerca VHIR
Laboratorio de Investigación Traslacional en el Cáncer de la Infancia y Adolescencia

SPAIN

Cataluña
BARCELONA

New epigenetic therapy for high-risk Neuroblastoma
Vall d'Hebron Institut de Recerca VHIR
Laboratorio de Investigación Traslacional en el Cáncer de la Infancia y Adolescencia

SPAIN

Cataluña
ESPLUGUES DE LLOBREGAT

Funded by an IRDiRC memberThe role of epigenetics in neuroblastoma pathogenesis: new molecular insights for the development of therapeutic strategies
Hospital Universitari Sant Joan de Déu
Grupo de investigación de biología molecular de los tumores del desarrollo

SPAIN

Cataluña
ESPLUGUES DE LLOBREGAT

Funded by an IRDiRC memberEvaluation of calcium-sensing receptor and parathyroid hormone-related protein as new therapeutic targets in neuroblastoma
Hospital Universitari Sant Joan de Déu
Grupo de investigación de biología molecular de los tumores del desarrollo

SPAIN

Comunidad Valenciana
VALENCIA

Funded by an IRDiRC memberBiotensegrity study in neuroblastoma
Universitat de València. Facultat de Medicina i Odontologia
Departamento de Patología

SWEDEN

Stockholms läns landsting
STOCKHOLM

Novel targeted therapy for childhood cancer with emphasis on Wip-1 in medulloblastoma and neuroblastoma
Karolinska Institutet - Solna
Department of Women's and Children's Health

SWEDEN

Stockholms läns landsting
STOCKHOLM

INTENT: innovative approach for treatment of neuroblastoma and medulloblastoma
Karolinska Institutet - Solna
Department of microbiology, tumor and cell biology

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

PK 2008 03: Pilot study to investigate the feasibility of 13-cis-retinoic acid pharmacokinetic monitoring in high-risk neuroblastoma patients
Northern Institute for Cancer Research, Medical School, Newcastle University
Northern Institute for Cancer Research

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

PK 2000 08: Pharmacokinetics of 13-cis retinoic acid following myeloablative therapy in neuroblastoma patients
Northern Institute for Cancer Research, Medical School, Newcastle University
Northern Institute for Cancer Research

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

PK 2000 07: Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients
Northern Institute for Cancer Research, Medical School, Newcastle University
Northern Institute for Cancer Research

GERMANY

Hamburg
HAMBURG

International HIT-MED Registry (I-HIT-MED) for Children, Adolescents, and Adults With Medulloblastoma, Ependymoma, Pineoblastoma, CNS-primitive Neuroectodermal Tumour
UKE - Universitätsklinikum Hamburg-Eppendorf
Klinik und Poliklinik für Pädiatrische Hämatologie und Onkologie

ITALY

CAMPANIA
NAPOLI

Cytogenetic characterization of central nervous system tumors
P.S.I. "Elena d'Aosta"
U.O.C. Servizio di Genetica

PORTUGAL

CENTRO
BRAGA

FRANCE

ILE-DE-FRANCE
ORSAY

DCD-CANC-CHILD: design of drug carrier and delivery control for cancer therapy of children
Université Paris-Sud
Institut de Chimie Moléculaire et des Matériaux d'Orsay

ITALY

LOMBARDIA
MILANO

RARECARE: surveillance of rare cancers in Europe (coordination)
Fondazione IRCCS Istituto Nazionale dei Tumori
S.S. di Epidemiologia Valutativa

UNITED KINGDOM

Tyne & Wear
NEWCASTLE UPON TYNE

EPOC: European paediatric oncology off-patent medicines consortium (coordination)
Northern Institute for Cancer Research, Medical School, Newcastle University
Northern Institute for Cancer Research

Multicentric Research projects